Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Akcea Therapeutics Inc. AKCA

Healthcare Biotechnology

Akcea Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are... see more

Add To Watchlist

Recent & Breaking News (NDAQ:AKCA)

Ionis and Akcea Present New Data from ATTR Amyloidosis Program at 16th International Symposium on Amyloidosis

PR Newswire March 26, 2018

Akcea Convenes First FCS Global Connection Summit

GlobeNewswire March 26, 2018

Ionis and Akcea Partner to Commercialize Inotersen for hATTR

PR Newswire March 15, 2018

Akcea Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire March 6, 2018

Akcea Therapeutics Recognizes Rare Disease Day by Spotlighting Several Historic “Firsts” for People Living with Familial Chylomicronemia Syndrome

GlobeNewswire February 28, 2018

Mid-Afternoon Market Update: Crude Oil Down 1.5%; Mallinckrodt Shares Climb After Strong Q4 Results

Benzinga.com February 27, 2018

Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2017

GlobeNewswire February 26, 2018

Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia Syndrome

GlobeNewswire February 15, 2018

Akcea Completes Enrollment in Phase 2b Study of AKCEA-APO(a)-LRx

GlobeNewswire February 7, 2018

New Research: Key Drivers of Growth for Tallgrass Energy GP, LP, Lithia Motors, Akcea Therapeutics, Meridian Bioscience, Myomo, and Liberty Media — Factors of Influence, Major Initiatives and Sustained Production

GlobeNewswire February 6, 2018

10 Stocks Moving In Monday's After-Hours Session

Benzinga.com February 5, 2018

Akcea Initiates Phase 2b Study of AKCEA-APOCIII-LRx in Patients with Hypertriglyceridemia and Established Cardiovascular Disease

GlobeNewswire January 5, 2018

Akcea Initiates Phase 2 Study of AKCEA-ANGPTL3-LRx in Patients with Hypertriglyceridemia, Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD)

GlobeNewswire December 14, 2017

Quotidian Technical Highlights on Selected Biotech Stocks -- Amgen, Alexion Pharma, AnaptysBio, and Akcea Therapeutics

PR Newswire December 14, 2017

Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

GlobeNewswire December 7, 2017

Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCS

GlobeNewswire November 15, 2017

Akcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program in Patients with Rare Hyperlipidemias

GlobeNewswire November 13, 2017

Akcea to Present at Stifel 2017 Healthcare Conference

GlobeNewswire November 7, 2017

Akcea Reports Financial Results and Highlights for Third Quarter 2017

GlobeNewswire November 6, 2017

Akcea and Ionis Report Positive Phase 1/2a Data with AKCEA-APOCIII-LRx

GlobeNewswire October 31, 2017